Navigation Links
Anti-obesity Drugs Claimed Additional Benefits on cardiometabolic Risk Factors Questioned

Additional beneficial effects on cardiometabolic risk factors beyond those expected from weight loss in trials of the anti-obesity drug rimonabant may not be due to the drug itself, reports an article in the June issue of Drug and Therapeutics Bulletin (DTB).

Advertisements for rimonabant (sold under the brand name Acomplia by Sanofi-Aventis) claim that an estimated 50% of the effects on cardiometabolic risk factors are beyond those expected from weight loss alone. But DTB argues that these effects are not proven to be due to the drug itself.

Also, no published trials have compared rimonabant with either of the other anti-obesity drugs orlistat or sibutramine. Instead, rimonobants effects on weight have been assessed in four double-blind trials comparing the drug with placebo.

The article says: In three of the trial reports, the authors state that the effects of rimonabant on HDL, triglycerides and HBA1c were partly independent of weight loss. However, it is not proven that any independent effect is wholly or partially attributable to rimonabant.

The article suggests that these observed effects might be related to increased activity based on the lifestyle advice given to participants at the start of the trials.

Furthermore, it is not known whether rimonabants effects on individual risk factors translate into a reduced long-term likelihood of cardiovascular events, the article adds.

. Rimonabant has not been directly compared with other, less expensive, drug treatments for obesity. Orlistat is the drug for obesity for which there is the most evidence for efficacy and safety to date, and we have previously concluded that it is a reasonable option for obese patients where diet and exercise and/or behavioural measures alone have failed.

Rimonabant is the most expensive of the anti-obesity drugs. A years treatment with rimonabant 20mg daily costs the NHS around 720, compar ed with 520 for orlistat 120 mg three times daily and 480-570 for sibutramine 10-15 mg daily.


'"/>




Related medicine news :

1. Anti-obesity drugs for FDA approval
2. Canada Confronts Obesity Head-on, Anti-obesity Campaign on Fast Track
3. Lean Protein Could Be Key to Obesity Drugs
4. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
5. Nasal Spray Could Take Drugs Direct to Brain.
6. Emphasis to ban Drugs ads by Doctors
7. Osteoporosis Drugs: right time to take-off
8. Drugs disrupt formation of blood vessels
9. Drugs to stop burgeon of HIV
10. Misleading Advertisements for Prescription Drugs
11. Drugs For Anthrax May Interfere With Oral Contraceptives
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... Market Analysis 2016 - Forecast to 2022" report to ... report contains up to date financial data derived from varied ... major trends with potential impact on the market during the ... segmentation which comprises of sub markets, regional and country level ...
Breaking Medicine Technology: